Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1830 • ACR Convergence 2021
Discontinuation of Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis and Psoriasis
Sophia Wolfe¹, Elizabeth Cheng², Kavya Ganuthula¹, Meika Fang³, Gail Kerr⁴, Jessica Walsh⁵, Elizabeth Chang⁶, Siba Raychaudhuri⁷, Kyle Brees², Robert Dellavalle¹, Andreas Reimold⁸ and Liron Caplan⁹, ¹Rocky Mountain Regional VAMC/University of Colorado School of Medicine, Aurora, CO, ²Rocky Mountain Regional VAMC, Aurora, CO, ³David Geffen School of Medicine at UCLA/West Los Angeles Veterans Affairs Medical Center (VAMC), Los Angeles, CA, ⁴Washington D.C., Veterans Affairs Medical Center (VAMC)/Georgetown and Howard Universities, Washington, DC, ⁵Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT, ⁶Phoenix VAMC, Phoenix, AZ, ⁷Sacramento Veterans Affairs Medical Center (VAMC)/University of California-Davis Health, Davis, CA, ⁸University of Texas – Southwestern Medical Center/Dallas Veterans Affairs Medical Center (VAMC), Dallas, TX, ⁹Rocky Mountain Regional Veterans Affairs Medical Center (VAMC)/University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease of the joints and skin that affects 1/1000 people in the US. Tumor necrosis factor-alpha (TNF-α)…
Abstract Number: 0046 • ACR Convergence 2021
Psoriatic Arthritis Skin Is Transcriptionally Different to Psoriasis Skin and Enriched in Immunoglobulin Transcripts
Hanna Johnsson¹, John Cole¹, Stefan Siebert¹, Iain McInnes² and Gerard Graham¹, ¹University of Glasgow, Glasgow, United Kingdom, ²University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom
Background/Purpose: Up to 30% of patients with psoriasis develop psoriatic arthritis (PsA). The traditional assumption is that the skin disease is the same in both…
Abstract Number: 0205 • ACR Convergence 2021
An Observational Study from the Perspective of Rheumatology in the Management of Patients with Psoriatic Arthritis in Turkey – LOOP Study
Ediz Dalkilic¹, Dilek Solmaz², Orhan Kucuksahin³, Erhan Capkin⁴, Mehmet Emin Derin⁵, Didem Arslan⁶, Fatih Noyan⁷, Nihan Belkis Coskun¹, Sadiye Murat⁸, Omer Faruk Sendur⁹, Meltem Alkan Melikoglu¹⁰, Savas Gursoy¹¹, Taciser Kaya¹², Ali Sahin¹³, Murat Karkucak⁴, Timur Pirildar¹⁴, Mustafa Ender Terzioglu¹⁵, Cemal Bes¹⁶ and Servet Akar², ¹Uludag University, School of Medicine – Bursa, Turkey, Bursa, Turkey, ²Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey, ³Ankara State Hospital, School of Medicine, Ankara, Turkey, ⁴Karadeniz Technical University, School of Medicine, Trabzon, Turkey, ⁵Sivas Numune Hospital, Sivas, Turkey, ⁶Cukurova University, School of Medicine – Adana, Turkey, Adana, Turkey, ⁷Nazilli State Hospital – Aydın, Turkey, Aydin, Turkey, ⁸Istanbul Medeniyet University, Goztepe Training and Research Hospital, İstanbul, Turkey, ⁹Adnan Menderes University, School of Medicine, Aydin, Turkey, ¹⁰Ataturk University, School of Medicine, Erzurum, Turkey, ¹¹Gaziantep University, School of Medicine – Gaziantep, Turkey, Gaziantep, Turkey, ¹²Saglik Bilimleri University, Izmır Bozyaka Trainig and Research Hospital – Izmir, Turkey, Izmir, Turkey, ¹³Sivas Cumhuriyet University, School of Medicine, Sivas, Turkey, ¹⁴Celal Bayar University, School of Medicine – Manisa, Turkey, Manisa, Turkey, ¹⁵Akdeniz University, School of Medicine, Antalya, Turkey, ¹⁶Saglik Bilimleri University, Basaksehir Cam and Sakura State Hospital – Istanbul, Turkey, Istanbul, Turkey
Background/Purpose: Available evidence suggests that timely and effective management of patients with psoriatic arthritis (PsA) can improve long-term outcomes. Current information on the factors which…
Abstract Number: 0577 • ACR Convergence 2021
Comorbidity Burden as Scored Using the Rheumatic Disease Comorbidity Index (RDCI) Is Associated with Varying Treatment Patterns in Patients with Inflammatory Arthritis – a Study Using the EHR-Derived Rheumatic and Arthritis Disease Information Registry (RADIR)
Diviya Rajesh, Deanna Jannat-Khah, Huong Do, Jonah Levine, Medha Barbhaiya, Lisa Mandl and Vivian Bykerk, Hospital for Special Surgery, New York, NY
Background/Purpose: Higher comorbidity burden (CB) has been associated with treatment choices in RA, but not assessed in populations including multiple forms of inflammatory arthritis (IA)…
Abstract Number: 1054 • ACR Convergence 2021
Metabolomics as an Innovative Tool for Cardiac Risk Stratification in Patients with Rheumatic Diseases: Results from a Pilot Study
Sorwe Mojtahed Poor¹, Lisa Hahnefeld², Frank Behrens³, Harald Burkhardt⁴, Michaela Köhm⁵, Geisslinger Gerd⁶ and Gurke Robert⁷, ¹University hospital Frankfurt Devision Rheumatology and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany, ²pharmazentrum frankfurt/ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt/Main, Germany, Frankfurt, Germany, ³Rheumatology & Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Fraunhofer Cluster Immune-Mediated Diseases (CIMD), Fraunhofer Cluster Immune-Mediated Diseases (CIMD), Frankfurt/Main, Germany, ⁴University hospital Frankfurt Devision Rheumatology and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany, ⁵University hospital Frankfurt Devision Rheumatology and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, ⁶Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany, ⁷pharmazentrum frankfurt/ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany
Background/Purpose: Patients with rheumatic diseases (RMD) face an increased cardiovascular (CV) mortality compared to the general population. Still, risk stratification based on traditional cardiovascular risk…
Abstract Number: 1327 • ACR Convergence 2021
Impact of BMI on Treatment Response Among PsA Patients Initiating TNF Inhibitors, IL17 Inhibitors and Oral Small Molecules
Emily Purcell¹, Soumya Reddy², Jessica Walsh³, Jose Scher⁴, Ethan Craig⁵, Elaine Husni⁶ and Alexis Ogdie¹, ¹University of Pennsylvania, Philadelphia, PA, ²NYU School of Medicine, New York, NY, ³Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT, ⁴New York University School of Medicine, New York, NY, ⁵University of Pennsylvania, Wallingford, PA, ⁶Cleveland Clinic, Cleveland, OH
Background/Purpose: Obesity is associated with poor response to treatment in patients with psoriatic arthritis (PsA), however, available data are mostly focused on tumor necrosis factor…
Abstract Number: 1344 • ACR Convergence 2021
Impact of Achieving Minimal Disease Activity on Patient-Reported Outcome Measures and Disease Activity Among Patients with Psoriatic Arthritis Treated with Biologic and Targeted Synthetic DMARDs
Alexis Ogdie¹, Robert McLean², Maya Marchese², Taylor Blachley², Laura Anatale-Tardiff³, Christopher Saffore⁴, Kevin Douglas⁵, Danny Quach⁵ and Philip Mease⁶, ¹University of Pennsylvania, Philadelphia, PA, ²CorEvitas, LLC, Waltham, MA, ³CorEvitas, Waltham, MA, ⁴AbbVie, North Chicago, IL, ⁵AbbVie Inc., North Chicago, IL, ⁶Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA
Background/Purpose: Minimal disease activity (MDA) is a common goal for disease control when managing PsA. The aim of this study was to assess the association…
Abstract Number: 1360 • ACR Convergence 2021
Ultrasound Demonstrates Continued Improvement in Psoriatic Arthritis Synovitis and Enthesitis with Secukinumab: 52-week Results from a Phase III Study
Maria Antonietta D'Agostino¹, Georg Schett², Corine Gaillez³, Carlos Guerrero⁴, PETRA HANOVA⁵, Tomas Cazenave⁶, Maria S. Stoenoiu⁷, Marina Backhaus⁸, Gael Mouterde⁹, Maarten Boers¹⁰, Anne-Marie Duggan¹¹, Punit Goyanka¹² and Philip Conaghan¹³, ¹Rheumatology, Fondazione Policlinico Universitario “Gemelli”, IRCCS, Rome, Italy, ²Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunology, Erlangen, Germany, Erlangen, Germany, ³Novartis Pharma AG, Basel, Switzerland, ⁴Dermatologico Country, Jalisco, Mexico, ⁵Department of Rheumatology, Institute of Rheumatology, Prague, Czech Republic, ⁶Instituto de Rehabilitación Psicofisica, Buenos Aires, Argentina, Buenos Aires, Argentina, ⁷Rheumatology department, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ⁸Department of Internal Medicine, Rheumatology and Clinical Immunology, Park-Klinik Weissensee Academic Hospital of the Charité, Berlin, Germany, Berlin, Germany, ⁹Rheumatology department, CHU Montpellier, Montpellier, France, ¹⁰Department of Epidemiology and Data Science, and Amsterdam Rheumatology and Immunology Center, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ¹¹Novartis Ireland Limited, Dublin, Ireland, Dublin, Ireland, ¹²Novartis Healthcare Pvt Ltd, Hyderabad, India, Hyderabad, India, ¹³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Power Doppler ultrasound (PDUS) is a sensitive non-invasive imaging tool to visualize a wide range of articular and periarticular inflammation in psoriatic arthritis (PsA).1,2…
Abstract Number: 1778 • ACR Convergence 2021
The Role of Cathepsin G in Joint Destruction in Patients with Psoriatic Arthritis
Mariela Geneva-Popova¹, Stanislava Popova¹ and Anastas Batalov², ¹Medical University, Faculty of Medicine, Department of Propedeutic of Internal Diseases, Plovdiv, Bulgaria, ²UMHAT KASPELA, Plovdiv, Bulgaria
Background/Purpose: Cathepsin G (CTSG) is a member of the serine protease family. It is stored in primary granules of myeloid cells, dendritic cells, plasma cells,…
Abstract Number: 1795 • ACR Convergence 2021
Validation of the Disease Activity Index for Psoriatic Arthritis (DAPSA) with a Quick QuantitativeC-reactive Protein Assay (Q-DAPSA) in Patients with Psoriatic Arthritis (PsA): A Prospective,national, Multicenter Study
Fabian Proft¹, Julia Schally², Henning Christian Brandt³, Jan Brandt-Jrgens⁴, Gerd Burmester¹, Hildrun Haibel⁵, Henriette Käding², Kirsten Karberg⁶, Susanne Lüders⁷, Burkhard Muche², Mikhail Protopopov¹, Judith Rademacher¹, Valeria Rios Rodriguez¹, Murat Torgutalp¹, Maryna Verba⁸ and Silke Zinke⁹, ¹Charité University Medicine Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, ³Praxis für Rheumatologie und Innere Medizin, Berlin, Germany, ⁴Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁵Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁶Praxis für Rheumatologie und Innere Medizin, Berlin, Germany, Berlin, Germany, ⁷Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, Berlin, Germany, ⁸Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, ⁹Rheumapraxis Berlin, Berlin, Germany
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease with multiple musculoskeletal and dermatological manifestations. Due to this multifaceted clinical appearance, international guidelines do not provide…
Abstract Number: 1812 • ACR Convergence 2021
Correlations Between Reductions in Fatigue Severity and Improvements in Physical Function and Clinical Response in Patients with Psoriatic Arthritis: Results from the Phase 3 DISCOVER Program
Arthur Kavanaugh¹, Yan Liu², Atul Deodhar³, Proton Rahman⁴, Philip Mease⁵, Philip S Helliwell⁶, Laure Gossec⁷, Alexa Kollmeier⁸, Elizabeth Hsia², May Shawi⁹ and Chenglong Han², ¹Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California San Diego, La Jolla, CA, ²Janssen Research & Development, LLC, Spring House, PA, ³Oregon Health & Science University, Portland, OR, ⁴Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ⁵Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁷Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ⁸Janssen Research & Development, LLC, La Jolla, CA, ⁹Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada
Background/Purpose: In patients (pts) with PsA, fatigue is a major driver of perceived impact of disease and has been identified as an important domain to…
Abstract Number: 1831 • ACR Convergence 2021
Predictors of Response, Adverse Events and Treatment Retention in Psoriatic Arthritis Patients Treated with Golimumab in a Prospective, Observational Registry
Proton Rahman¹, Isabelle Fortin², Regan Arendse³, Derek Haaland⁴, Arthur Karasik⁵, Maqbool Sheriff⁶, Emmanouil Rampakakis⁷, Meagan Rachich⁸, Francois Nantel⁹, Allen Lehman⁸ and Odalis Asin-Milan⁸, ¹Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ²CREQ, Rimouski, QC, Canada, ³University of Saskatchewan, Saskatoon, SK, Canada, ⁴McMaster University, Hamilton, Ontario and The Waterside Clinic, Oro Medonte, ON, Canada, ⁵Arthur Karasik Medicine Professional Corporation, Toronto, ON, Canada, ⁶Nanaimo Regional Hospital, Nanaimo, BC, Canada, ⁷JSS Medical Research, Montréal, QC, Canada, ⁸Janssen Inc., Toronto, ON, Canada, ⁹., Montréal, QC, Canada
Background/Purpose: The Biologic Treatment Registry Across Canada (BioTRAC) was a prospective, observational registry that enrolled psoriatic arthritis (PsA) patients treated with subcutaneous golimumab (GLM) between…
Abstract Number: 0049 • ACR Convergence 2021
CC-99677, a Novel, Selective, Oral MK2 Inhibitor, Sustainably Reduces Pro-inflammatory Cytokine Production and Ameliorates Inflammation in the Mannan-Induced Murine Model of Psoriasis and Psoriatic Arthritis
Rajula Gaur, Kofi Mensah, Jason Stricker, Anastasia Parton, Dorota Cedzik and Francisco Ramírez-Valle, Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Mitogen-activated protein kinase-activated protein kinase-2 (MK2), a direct downstream target of p38, has been identified as a promising candidate for treatment of inflammatory diseases.…
Abstract Number: 0225 • ACR Convergence 2021
Prevalence of Sexual Dysfunction and Depression in German Patients with Psoriasis and Psoriatic Arthritis – Results of the PIPPA Study
Sebastian Saur¹, Alexandra Schloegl², Caroline Höppner³, Anastasia Gubar², Katharina Meier⁴, Matthias Hahn² and Jorg Henes², ¹Universtiy Hostpiatl Tübingen, Tuebingen, Germany, ²University Hospital Tuebingen, Tuebingen, Germany, ³Charite Berlin, Berlin, Germany, ⁴Department of Dermatology, Venereology and Allergology – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, Berlin, Germany
Background/Purpose: As known chronic inflammatory diseases have an impact on sexuality. To date, there are only a few studies from North and Latin America which…
Abstract Number: 0633 • ACR Convergence 2021
Value of the Routine Assessment of Patient Index Data 3 (RAPID3) as a Disease Activity Measure in Patients with Psoriatic Arthritis
Johny Fares¹, Andrea Healy¹ and Martin Bergman², ¹Main Line Health, Wynnewood, PA, ²Martin Jan Bergman, MD, Ridley Park, PA
Background/Purpose: The RAPID3 is a patient-reported pooled index of three measures: function, pain, and patient global estimate of status, that is used to classify disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].